The panel discussion following the first plenary session was thought provoking. A number of interesting questions were posed, revolving around the central theme of treating cancer in times of COVID-19. These are briefly summarised below: **Key messages:** • Several studies suggest that there is no increased risk of COVID-19 for patients receiving chemotherapy. Although factors such as cancer type, age and sex need to be taken into account. One of the studies cited was from The Lancet(1). • Many studies do not include a non-cancer control group and are of small size meaning the hazard ratio is large. Increased understanding and treating with caution may be necessary. • Younger cancer patients seem to be at a greater relative risk than older cancer patients of COVID-19 mortality and their risk should be assessed accordingly. • Testing systems should allow for regular testing and a COVID-free hospital visit or stay. • Ideally patients would receive a COVID-19 test for every visit. Chemotherapy patients can receive a test for every cycle of treatment. However, patients requiring intense hospital visits, such as early phase trial patients and radiotherapy patients, pose more of a problem. • Risk needs to be reduced as much as possible but may never be zero. • It is important that patients and oncologists do not get frightened by the perceived risk of getting treatment in hospital and as a result, patients fail to receive best possible treatment, resulting in worse outcomes. • Staff testing also important. Still not in a situation where staff tests are weekly. Staff may need to be prioritised based on patient risk e.g. studies have shown that haematological patients are at higher risk so staff in haematological centres should be swabbed every second day. • Patients who stay swab positive after 21 days or become positive once again following a negative result also pose a problem. CCP’s initial studies have found that the virus cannot be isolated from these patients which may suggest that they are not infectious. However, not enough immunocompromised patients have been studied to confidently state that there are no subgroups that stay infectious. Further studies are required. • COVID data may affect studies such as NOTION carried out by dECMT which involves the in-home measurement of cytokine levels. Any data may assist in the primary objective of the dECMT to assess the technology and in-home monitoring system. dECMT happy to collect samples and data from COVID patients. • Everything dECMT is developing will be open source and available to any country that wish to collaborate and use the software. 1 - COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Lee, Lennard YW et al. The Lancet, Volume 395, Issue 10241, 1919 - 1926